Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Intellia Therapeutics's Sloan Ratio for the quarter that ended in Jun. 2026 was -0.57%.
Warning Sign:
When sloan ratio (-29.21)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Jun. 2026, Intellia Therapeutics has a Sloan Ratio of -0.57%, indicating the company is in the safe zone and there is no funny business with accruals.
Intellia Therapeutics (NAS:NTLA) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Intellia Therapeutics has a Sloan Ratio of -0.57%, indicating the company is in the safe zone and there is no funny business with accruals.
Intellia Therapeutics Sloan Ratio % Related Terms
Intellia Therapeutics Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Intellia Therapeutics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Intellia Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Intellia Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Intellia Therapeutics's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was -101.324 (Sep. 2025 ) + -95.786 (Dec. 2025 ) + -96.231 (Mar. 2026 ) + -106.634 (Jun. 2026 ) = $-399.98 Mil.
Intellia Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was -76.899 (Sep. 2025 ) + -69.285 (Dec. 2025 ) + -117.346 (Mar. 2026 ) + -83.113 (Jun. 2026 ) = $-346.64 Mil.
Intellia Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -0.741 (Sep. 2025 ) + 27.534 (Dec. 2025 ) + 66.31 (Mar. 2026 ) + -141.572 (Jun. 2026 ) = $-48.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intellia Therapeutics (NTLA) has a Sloan Ratio % of -0.57% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Sloan Ratio % too high?
Intellia Therapeutics' current Sloan Ratio % is -0.57%. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Sloan Ratio % compare to SEPN and AVBP?
Intellia Therapeutics' Sloan Ratio % of -0.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Sloan Ratio % is -0.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.76, compared to a current price of $11.60 — trading 15.7% below its estimated fair value. The current Sloan Ratio % is -0.57%. Intellia Therapeutics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Sloan Ratio % is -0.57% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intellia Therapeutics (NTLA) Overvalued in 2026?
Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued.
The current stock price of $11.60 is trading 15.7% below its estimated GF Value™ of $13.76.
GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.
Key valuation signals for NTLA:
Sloan Ratio %: -0.57%
GF Value™: $13.76 vs. price of $11.60 (15.7% below fair value)
No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score
Get the complete analysis for NTLA
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTLA has been successfully added to your 
